Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Van Belle

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Circulation|October 1, 1981
Cardioprotective effects of lidoflazine during 1-hour normothermic global ischemiaW Flameng, W Daenen, M Borgers, et al.
The Journal of Biological Chemistry|June 25, 1985
Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sitesD de Chaffoy de Courcelles, J E Leysen, F De Clerck, et al.
Chemico-Biological Interactions|October 1, 1978
DL-2-Oxo-3-(2-mercaptoethyl)-5-phenylimidazolidine. A sulfhydryl metabolite of levamisole that interacts with microtubulesM De Brabander, F Aerts, G Geuens, et al.
Hypertension (Dallas, Tex. : 1979)|April 1, 1996
Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosineG A Rongen, J W Lenders, J Lambrou, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 10, 1998
Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazineE Snoeck, K Ver Donck, P Jacqmin, et al.
The American Journal of Physiology|April 1, 1993
Adenine nucleotide degradation in ischemic rabbit lung tissueP De Leyn, T Lerut, H Schreinemakers, et al.
The Journal of Clinical Investigation|February 1, 1995
Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotectionG A Rongen, P Smits, K Ver Donck, et al.
Cardiovascular Research|September 1, 1984
Cardioprotective effects of mioflazine during 1 h normothermic global ischaemia in the canine heartW Flameng, R Xhonneux, H Van Belle, et al.
British Journal of Clinical Pharmacology|November 1, 1996
The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazineE Snoeck, P Jacqmin, A Van Peer, et al.
British Journal of Clinical Pharmacology|June 1, 1997
Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion ratesE Snoeck, V Piotrovskij, P Jacqmin, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Circulation|October 1, 1981
Cardioprotective effects of lidoflazine during 1-hour normothermic global ischemiaW Flameng, W Daenen, M Borgers, et al.
The Journal of Biological Chemistry|June 25, 1985
Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sitesD de Chaffoy de Courcelles, J E Leysen, F De Clerck, et al.
Chemico-Biological Interactions|October 1, 1978
DL-2-Oxo-3-(2-mercaptoethyl)-5-phenylimidazolidine. A sulfhydryl metabolite of levamisole that interacts with microtubulesM De Brabander, F Aerts, G Geuens, et al.
Hypertension (Dallas, Tex. : 1979)|April 1, 1996
Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosineG A Rongen, J W Lenders, J Lambrou, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 10, 1998
Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazineE Snoeck, K Ver Donck, P Jacqmin, et al.
The American Journal of Physiology|April 1, 1993
Adenine nucleotide degradation in ischemic rabbit lung tissueP De Leyn, T Lerut, H Schreinemakers, et al.
The Journal of Clinical Investigation|February 1, 1995
Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotectionG A Rongen, P Smits, K Ver Donck, et al.
Cardiovascular Research|September 1, 1984
Cardioprotective effects of mioflazine during 1 h normothermic global ischaemia in the canine heartW Flameng, R Xhonneux, H Van Belle, et al.
British Journal of Clinical Pharmacology|November 1, 1996
The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazineE Snoeck, P Jacqmin, A Van Peer, et al.
British Journal of Clinical Pharmacology|June 1, 1997
Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion ratesE Snoeck, V Piotrovskij, P Jacqmin, et al.
Pageof 7